JPJerome Perrard

Jerome Perrard

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Jerome Perrard has a total of 25 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Small RNA profiling reveals inflammatory and mitochondrial changes in aging β cells and islet macrophages

    by Claudiane Guay, Jérôme Perrard, Eleonora Mangano, Véronique Menoud, Alessandra Galli, Francesco Alabiso, Elena Aiello, Daniela Fignani, Francesco Dotta, Susan Bonner-Weir, et al.

    Aging is associated with functional decline and senescence of pancreatic β-cells. Modulation of post-transcriptional mechanisms is a hallmark of aging. Here we analyze the small non-coding RNA (sncRNA) repertoire of FACS-sorted β-cells and islet-resident macrophages (iMACs) from 3-, 12-, and 22-month-old mice, and of senescence-associated β-galactosidase–positive β-cells from 8-month-old mice. We show that senescent β-cells display distinct sncRNA signatures partially overlapping with aging-associated ones. MiRNAs linked to diabetic conditions and islet inflammation are commonly modulated in both contexts. Cytokine exposure followed by washout partially recapitulates the aging sncRNA profile in vitro. Upregulation of inflammatory miR-146a-5p and downregulation of proliferative miR-181a-5p are shared across aged metabolic tissues, whereas upregulation of the miR-143-3p/miR-145-5p cluster, which is associated with insulin responses, is β-cell specific. Aging also remodels the tRNA-derived fragment (tRF) repertoire, with mitochondrial tRFs markedly increased. iMACs from aged mice show elevated anti-inflammatory associated miRNAs and mitochondrial tRFs, suggesting adaptive reprogramming. Overall, our findings reveal extensive sncRNA remodeling during islet aging.

  • Régulation de l'expression des oncogènes du papillomavirus humain de type 16 : étude dans des lignées cellulaires de cancers du col de l'utérus traitées avec un agent déméthylant

    by JérÔmE Perrard

    Les papillomavirus humains (HPV) sont des petits virus non enveloppés à ADN double brin, qui infectent les épithéliums cutanés et muqueux. Très largement répandus dans la population humaine, les infections sont la plupart du temps asymptomatiques, tandis qu'une minorité provoquent des verrues cutanées, des condylomes acuminés et des carcinomes. Les cancers induits par HPV représentent 640 000 cas en 2012 dans le monde et sont localisés au niveau anogénital et au niveau des voies aérodigestives supérieures.La transformation des cellules est induite en particulier par la surexpression de deux oncoprotéines virales : E6 et E7, qui sont nécessaires à l'initiation, la promotion et la progression du phénotype cancéreux. Leur extinction provoque d'ailleurs la mort des cellules cancéreuses. E6 et E7 favorisent par exemple la dégradation de p53 et pRb, induisant ainsi une prolifération non contrôlée et accrue des cellules infectées. Mais les deux oncoprotéines virales interagissent aussi avec plus de 150 partenaires protéiques et dérégulent l'homéostasie cellulaire. Fait intéressant, E6 et E7 modulent l'expression de nombreuses protéines impliquées dans l'établissement des marques épigénétiques, impliquées dans la régulation de l'expression des gènes. D'ailleurs, la surexpression des oncoprotéines virales peut être liée à la méthylation de l'ADN d'une partie du génome viral.Puisque E6 et E7 détournent la machinerie épigénétique de la cellule, l'objectif du travail de thèse a été d'étudier les mécanismes moléculaires régulant l'expression des oncoprotéines lors du traitement des cellules de cancers du col par un agent déméthylant de l'ADN, le 5-aza-2'-déoxycytidine (5azadC).Dans des cellules issues de cancers du col de l'utérus, nous avons observé qu'un traitement déméthylant induisait une répression de la protéine E6 et une déstabilisation de ses transcrits, suggérant l'implication d'un miARN. Parmi les miARN ciblant les transcrits viraux, le miR-375 était le plus susceptible d'être impliqué dans la déstabilisation des transcrits car (i) la méthylation de son promoteur augmente avec la gravité des lésions du col de l'utérus, (ii) il cible les transcrits viraux au niveau de cinq régions différentes, et (iii) son expression est augmentée lors du traitement de cellules dérivées du cancer du col de l'utérus avec le 5azadC. Il s'est avéré que le miR-375 était effectivement impliqué dans la répression partielle des transcrits viraux lors du traitement. Les résultats de cette étude suggèrent par ailleurs qu'un autre mécanisme moléculaire pourrait être impliqué dans cette répression. C'est pourquoi, dans un deuxième temps, nous avons étudié l'implication possible d'un facteur de transcription, TBX2, dans la répression des transcrits viraux. Bien que le taux transcriptionnel de TBX2 soit augmenté lors du traitement des cellules avec des fortes concentrations de 5azadC, nos résultats suggèrent que la protéine n'est pas exprimée dans les cellules, même après traitement, et que TBX2 ne régule pas l'activité du promoteur viral intégré au génome cellulaire.Le traitement des cellules par l'agent déméthylant entraîne aussi une perte de viabilité en particulier des cellules Ca Ski. En effet, le 5azadC induit un blocage du cycle en G2/M dans ces cellules, une augmentation du pourcentage de cellules en Sub-G1 et un clivage de la PARP. Si le 5azadC est déjà utilisé en clinique pour le traitement d'autres cancers, nos données apportent un éclairage nouveau sur les mécanismes moléculaires du 5azadC dans les cancers induits par HPV, qui pourraient ainsi être traités par cette molécule.

  • Open Access

    Role of small intronic RNAs in the crosstalk between immune cells and β-cells during type 1 diabetes development

    by Shagun Poddar, Flora Brozzi, Cristina Cosentino, Cécile Jacovetti, Claudiane Guay, Jérôme Perrard, Romano Regazzi

    Small non-coding RNAs, such as microRNAs and tRNA-derived fragments, are key regulators of cellular processes, but the functions of small intronic RNAs (sinRNAs), a recently identified RNA class, remain largely unknown. Here, we report that two sinRNAs, sinR-D and sinR-T, are upregulated in pancreatic β-cells of NOD mice, a well-established model of type 1 diabetes. Using in vivo RNA-tagging, we demonstrate that these sinRNAs are packaged into extracellular vesicles released by infiltrating CD4⁺ T lymphocytes and subsequently delivered to β-cells during the early stages of autoimmune attack. Functional analyses revealed that overexpression of sinR-T has little effect on β-cell viability, whereas sinR-D markedly increases β-cell apoptosis. This finding suggests that the transfer of sinR-D contributes to β-cell destruction and the onset of type 1 diabetes. Furthermore, pull-down experiments with biotinylated sinRNAs identified Ago2, a core component of the RNA-induced silencing complex (RISC), as a binding partner of sinR-D, indicating mechanistic parallels with microRNA-mediated regulation. Collectively, our data uncover a novel role for sinRNAs as extracellularly transferred regulators of β-cell fate, expanding the repertoire of small RNAs implicated in the initiation of type 1 diabetes.

  • Open Access

    Small non-coding RNA profiling reveals inflammatory and mitochondrial related changes in aging β-cells and islet macrophages

    by Claudiane Guay, Jérôme Perrard, Eleonora Mangano, Véronique Menoud, Elena Aiello, Daniela Fignani, Francesco Dotta, Susan Bonner-Weir, Guido Sebastiani, Cristina Aguayo-Mazzucato, et al.

    Aging is accompanied by functional decline and increased senescence of pancreatic β-cells. These changes may be influenced by islet-resident macrophages (iMACs) that remodel tissue in response to environmental cues. To explore the molecular mechanisms underlying β-cell aging and senescence, we profiled small non-coding RNAs (sncRNAs) in FACS-sorted β-cells and iMACs from 3-, 12-, and 22-month-old mouse islets or from senescence-associated βgal (SA-βgal) positive β-cells of 8-month-old mice. Overall, senescent β-cells displayed distinct sncRNA signatures that only partially overlapped with those of aging. However, several miRNAs previously found to be deregulated in obese or diabetic conditions were modulated in both aging and senescent β-cells, including upregulation of miRNAs linked to inflammation. In vitro exposure to pro-inflammatory cytokines partially reproduced these profiles. Aging also reshaped the β-cell tRNA-derived fragment (tRF) pool, enhancing global mitochondrial tRF levels. Interestingly, some changes in miRNAs and tRFs were β-cell specific, whereas others occurred also in other aged metabolic tissues. iMACs also showed age-related sncRNA remodeling, including upregulation of anti-inflammatory miRNAs and mitochondrial tRFs, suggesting adaptive immune reprogramming. Together, these data reveal a profound, coordinated reshaping of the sncRNA landscape in β-cells and iMACs during aging, offering new insights into molecular mechanisms driving age-related islet dysfunction.

  • Open Access

    Deltex and RING-UIM E3 ligases cooperate to create a ubiquitin-ADP-ribose hybrid mark on tankyrase, promoting its stabilization

    by Jerome Perrard, Kevin Gao, Katherine Ring, Susan Smith

    ADP-ribosylation can occur as mono-ADP-ribose (MAR) or be extended into poly-ADP-ribose (PAR). Tankyrase, a PAR transferase, adds PAR to itself and other proteins targeting them for proteasomal degradation via the PAR-binding E3 ligase RNF146. This degradation can be counteracted by RING-UIM E3 ligases RNF114 and RNF166, although the process is unclear. Here, we identify a mechanism that can regulate the balance between MAR and PAR on tankyrase to control degradation. We show that Deltex E3 ligases DTX2 and DTX3 catalyze monoubiquitylation of tankyrase in cells. This ubiquitylation occurs, not on a (canonical) lysine, but rather on MAR, creating a monoubiquitin-MAR hybrid mark. RNF114 and RNF166 recognize this mark using a unique hybrid reader domain and further diubiquitylate it. This ubiquitylation of MAR, which occurs near the ADP-ribose addition site, prevents PAR formation, antagonizing the action of the PAR-binding E3 ligase RNF146 and stabilizing tankyrase. These findings reveal an interplay between ubiquitin, ADP-ribose, and E3 ligases in cellular signaling.


  • Open Access

    Deltex and RING-UIM E3 ligases cooperate to create a ubiquitin-ADP-ribose hybrid mark on tankyrase, promoting its stabilization

    by Jerome Perrard, Kevin Gao, Katherine Ring, Susan Smith

    : ADP-ribosylation is a key post-translational modification that impacts diverse cellular pathways. The modification can occur as mono-ADP-ribose (MAR) or be extended into poly-ADP- ribose (PAR). Tankyrase, a PAR transferase, adds PAR to itself and other proteins to influence their function and stability by tagging them for proteasomal degradation via the PAR-binding E3 ligase RNF146. This degradation can be counteracted by RING-UIM E3 ligases RNF114 and RNF166, though the process is unclear. Here we identify a new mechanism that can regulate the balance between MAR and PAR on tankyrase to control degradation. We show that Deltex E3 ligases DTX2 and DTX3 catalyze monoubiquitylation of tankyrase in cells. This ubiquitylation occurs, not on a (canonical) lysine, but rather on mono-ADP-ribose, creating a monoubiquitin- MAR hybrid mark. RNF114 and RNF166 recognize this mark using a unique hybrid reader domain comprising two binding sites - one for MAR and one for ubiquitin - and further diubiquitylate it. This ubiquitylation of MAR, which occurs near the ADP-ribose addition site, prevents PAR formation, antagonizing the action of the PAR-binding E3 ligase RNF146 and stabilizing tankyrase. These findings reveal a novel interplay between ubiquitin, ADP-ribose, and E3 ligases in cellular signaling.


  • Open Access

    Multiple E3 ligases control tankyrase stability and function

    by Jerome Perrard, Susan Smith

    Tankyrase 1 and 2 are ADP-ribosyltransferases that catalyze formation of polyADP-Ribose (PAR) onto themselves and their binding partners. Tankyrase protein levels are regulated by the PAR-binding E3 ligase RNF146, which promotes K48-linked polyubiquitylation and proteasomal degradation of tankyrase and its partners. We identified a novel interaction between tankyrase and a distinct class of E3 ligases: the RING-UIM (Ubiquitin-Interacting Motif) family. We show that RNF114 and RNF166 bind and stabilize monoubiquitylated tankyrase and promote K11-linked diubiquitylation. This action competes with RNF146-mediated degradation, leading to stabilization of tankyrase and its binding partner, Angiomotin, a cancer cell signaling protein. Moreover, we identify multiple PAR-binding E3 ligases that promote ubiquitylation of tankyrase and induce stabilization or degradation. Discovery of K11 ubiquitylation that opposes degradation, along with identification of multiple PAR-binding E3 ligases that ubiquitylate tankyrase, provide insights into mechanisms of tankyrase regulation and may offer additional uses for tankyrase inhibitors in cancer therapy.